Posted by Michael Wonder on 19 Jul 2021
Imfinzi approved in China for the treatment of extensive-stage small cell lung cancer
19 July 2021 - Only PD-1/PD-L1 immunotherapy to demonstrate both a significant survival benefit and improved response rate in combination with a choice of chemotherapies
AstraZeneca’s Imfinzi (durvalumab) has been approved in China for the first-line treatment of adult patients with extensive-stage small cell lung cancer, in combination with standard of care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin).
